Systemic Delivery, Local Effects

_

Targeting Intractable Pathways
in the TME

President, CEO, and Cofounder

Chief Development Officer
Head of Research

Vice President, Technical Operations

Lead Oncology Advisor

Director,
Analytical Development

Associate Director,
Process Development

Chief Business Officer

Head of Operations

Director, Molecular and Microbiology

Board Chair

Greg Barton, PhD

Paul Rennert, PhD

Samuel Miller, MD

Michel Streuli, PhD

Denise Monack, PhD

Mario Sznol, MD

Alessandra Cesano, MD, PhD
Lead Oncology Advisor

Jean-Pierre Bizzari, MD

Mark Frohlich, MD
 

Lawrence Fong, MD

Joel Randolph Hecht, MD

Jason J Luke, MD

Mario Sznol, MD

Actym Therapeutics Announces Significant Expansion of Senior Leadership

BERKELEY, Calif., May 12, 2022, PRNewswire

Actym Therapeutics Announces Participation in May Investor Conferences

BERKELEY, Calif.  May 3, 2022

Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym's Lead Candidate for the Treatment of Solid Tumors

BERKELEY, Calif. and AMSTERDAM, Feb. 28, 2022

Actym Therapeutics CEO Dr. Christopher Thanos named one of the “Top 25 Biotech CEOs of 2022”

BERKELEY, Calif., Feb 17, 2022

Actym Therapeutics Announces Issuance of US Patent

BERKELEY, Calif., Feb 14, 2022

Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC

BERKELEY, Calif., Nov. 12, 2021 

Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer

BERKELEY, Calif., Nov. 11, 2021